New ALS drug usnoflast enters key trial to slow deadly disease

NCT ID NCT07023835

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study tests whether the drug usnoflast can slow the progression of ALS, a severe nerve disease that causes muscle weakness and breathing problems. About 240 adults with ALS will receive either usnoflast or a placebo for 36 weeks. Researchers will measure changes in daily function and survival to see if the drug helps control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Zydus 100

    ACTIVE_NOT_RECRUITING

    Québec, Quebec, QC H4A 3T2, Canada

  • Zydus 101

    NOT_YET_RECRUITING

    Toronto, Ontario, ON M4N 3M5, Canada

  • Zydus US001

    RECRUITING

    Dallas, Texas, 75206, United States

  • Zydus US002

    RECRUITING

    Houston, Texas, 77030, United States

  • Zydus US003

    RECRUITING

    Winston-Salem, North Carolina, 27157, United States

  • Zydus US004

    RECRUITING

    Richmond, Virginia, 23298, United States

  • Zydus US005

    RECRUITING

    New Britain, Connecticut, 06053, United States

  • Zydus US006

    RECRUITING

    Detroit, Michigan, 48202, United States

  • Zydus US007

    NOT_YET_RECRUITING

    Atlanta, Georgia, 30322, United States

  • Zydus US008

    NOT_YET_RECRUITING

    Orange, California, 92868, United States

  • Zydus US009

    NOT_YET_RECRUITING

    Pittsburgh, Pennsylvania, 15212, United States

  • Zydus US010

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Zydus US011

    RECRUITING

    Seattle, Washington, 98122, United States

  • Zydus US012

    RECRUITING

    Tampa, Florida, 80045, United States

  • Zydus US013

    NOT_YET_RECRUITING

    San Francisco, California, 94109, United States

  • Zydus US014

    RECRUITING

    Lincoln, Nebraska, 68510, United States

  • Zydus US015

    RECRUITING

    La Jolla, California, 92037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.